Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Assenagon Asset Management S.A. increased its stake in Stoke Therapeutics by 36.4% in Q4 to 1,227,723 shares (about 2.15% of the company), valued at roughly $38.97 million.
• Stoke Therapeutics has a market capitalization of $2.0 billion, a one‑year trading range of $5.35–$40.22 and 50/200‑day moving averages near $32.78/$30.37; analysts hold a consensus "Moderate Buy" with an average price target of $41.83.
• Company insiders have sold 69,699 shares worth about $2.53 million over the past 90 days and collectively own 9.50% of the stock.

Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 36.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,227,723 shares of the company's stock after purchasing an additional 327,451 shares during the quarter. Assenagon Asset Management S.A. owned about 2.15% of Stoke Therapeutics worth $38,968,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in STOK. Vanguard Group Inc. boosted its holdings in shares of Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company's stock valued at $74,351,000 after buying an additional 217,616 shares in the last quarter. Marshall Wace LLP raised its stake in Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company's stock worth $26,111,000 after acquiring an additional 168,771 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock worth $11,053,000 after acquiring an additional 293,072 shares in the last quarter. Polar Capital Holdings Plc lifted its position in Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company's stock valued at $31,102,000 after acquiring an additional 439,824 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Stoke Therapeutics by 7.9% in the second quarter. Geode Capital Management LLC now owns 972,921 shares of the company's stock valued at $11,044,000 after acquiring an additional 70,935 shares during the last quarter.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $33.79 on Thursday. The company has a market capitalization of $2.00 billion, a P/E ratio of -281.56 and a beta of 1.07. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $40.22. The company's fifty day moving average is $32.78 and its two-hundred day moving average is $30.37.

Insider Activity

In related news, insider Arthur Tzianabos sold 4,355 shares of the business's stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total value of $174,200.00. Following the transaction, the insider owned 31,339 shares in the company, valued at $1,253,560. The trade was a 12.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Barry Ticho sold 6,686 shares of the company's stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $209,539.24. Following the sale, the insider directly owned 40,798 shares of the company's stock, valued at approximately $1,278,609.32. This represents a 14.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 69,699 shares of company stock valued at $2,526,714. Insiders own 9.50% of the company's stock.

Analyst Ratings Changes

STOK has been the topic of several research reports. Wedbush raised their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an "outperform" rating in a report on Tuesday, March 17th. BTIG Research reissued a "buy" rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Thursday, March 19th. UBS Group set a $50.00 target price on Stoke Therapeutics in a research report on Monday, December 15th. Weiss Ratings restated a "hold (c-)" rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. Finally, Loop Capital set a $35.00 price target on Stoke Therapeutics in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $41.83.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.